



SDI Review Form 1.6

Journal Name:	Asian Hematology Research Journal
Manuscript Number:	Ms_AHRJ_49637
Title of the Manuscript:	Platelet Indices and Antiphospholipid Syndrome in Patients with Recurrent Pregnancy Loss
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>Introduction</p> <ul style="list-style-type: none"> - RPL – Please review the definition, most of the international bodies are at a consensus that ≥ 3 miscarriages account for RPL (if you are following a reference which says ≥ 2 miscarriages, please cite the same in the text) <p>Methods:</p> <ul style="list-style-type: none"> - Please specify if the testing for lupus anticoagulant and anti cardiolipin antibody was done once or twice, and if it was done only once, please specify how was a diagnosis of APLA / APS (anti phospholipid antibody syndrome) made with just one positive test - Please mention the status of Institutional Ethics Committee approval in methods section <p>Statement</p> <ul style="list-style-type: none"> - Please mention the source of funding and conflict of interest of all authors. 	
Minor REVISION comments	<p>Abstract:</p> <ul style="list-style-type: none"> - Line 16, 17 – Please mention the full form when an abbreviation is used for the first time in the text - Line 17 – 18, as these tests were done for confirmation of APLA, they need to be placed before mentioning platelet indices ie. at the beginning of methods after inclusion and exclusion criteria - Line 19 – Please write the full form - Line 20 – Please mention the abbreviation at the first use <p>Introduction</p> <ul style="list-style-type: none"> - Line 43 – abs antibodies <p>Materials:</p> <ul style="list-style-type: none"> - Line 64 – in EDTA container / vacutainer - Line 93 – Please write the full form of gpl and mpl - Line 95 - PDW did not attain any statistically significant difference 	
Optional/General comments	<p>Well written paper, can be considered for publication by the editor.</p> <p>It is mandatory as per the journal's guidelines to line number the manuscript before submitting it for review, as the manuscript was not line numbered, the reviewer has line numbered the manuscript for your perusal.</p>	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	



[SDI Review Form 1.6](#)

Reviewer Details:

Name:	<i>Mohammed Ismail Khan</i>
Department, University & Country	<i>ESIC Medical College, India</i>